Anti-inflammation effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients
Biochem Biophys Res Commun 2020;524:3549
The release of these new GLP1-based chimeras is expected to result in higher clinical efficacy with lower adverse effects for the treatment of obesity, and, likely, its pharmacological action will be extended to other comorbidities such as type II diabetes, nephropathy, and non-alcoholic fatty liver disease or steatohepatitis [34,35,111,126,132,134,135]
This is where ceramides come in
[8] [9] For weight management, NICE technology appraisals (TA875 for semaglutide [Wegovy] and TA664 for liraglutide [Saxenda]) provide specific eligibility criteria